Alcohol Use DisorderNCT05747703
Telehealth Treatment for Alcohol Use Disorder
A study testing Ria Treatment Platform in people with Alcohol Use Disorder and Alcohol Dependence, run by Ria Health at 1 site in United States.
Trial summary
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alcohol Use Disorder, Alcohol Dependence, Alcoholism
- What is being tested?
- Ria Treatment Platform
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 135 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jan 2024to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- alcohol use disorder
Who cannot join
- inability to provide informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.
- Conditions
- Alcohol Use Disorder, Alcohol Dependence, Alcoholism
- Being tested
- Ria Treatment Platform
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ria Treatment PlatformCombination product
combined medication, coaching, education, and monitoring
| Study group | Role | What they receive |
|---|---|---|
| Ria Treatment Platfrom | Experimental | The Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer. Receives: Combination Product: Ria Treatment Platform |
| waitlist control | No intervention | Patients in this arm will not be provided treatment during the study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent of subjects without heavy drinking days
Heavy drinking is defined as 5 or more standard drinks per day for men and 4 or more standard drinks per day for women, as assessed by the Timeline Followback.
Measured: Final 4 weeks of the 12-week trial period
Secondary outcomes (2)
Proportion of abstinent days
Any drinking as assessed by the Timeline Followback
Measured: 12-week trial period
Liver function (ALT, AST, GGT)
Measures of liver function.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2023
- Study start31 Jan 2024
- Primary completion21 Apr 2026
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- participants will be randomly assigned in a 1:1 to the Ria Treatment Platform or a waitlist control condition
- Masking
- None (open label)
- Enrolment
- 135 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ria Health
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), Stanford University, University of Washington
- Responsible party
- Sponsor
- Investigators
- John Mendelson, MD, Principal investigator, Ria Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05747703
- Sponsor's protocol ID
- 1A
- Status last verified
- Jun 2026
- First submitted
- 17 Feb 2023
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder
- ClinicalTrials.gov ID
- NCT05747703
- Acronym / sponsor ID
- 1A
- Conditions
- Alcohol Use Disorder, Alcohol Dependence, Alcoholism
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 135 participants (actual)
- Lead sponsor
- Ria HealthIndustry (pharma, biotech, devices)
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), Stanford University, University of Washington
- Study start
- 31 Jan 2024 (actual)
- Primary completion
- 21 Apr 2026 (actual)
- Study completion
- Sep 2026 (estimated)
- First posted
- 28 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- participants will be randomly assigned in a 1:1 to the Ria Treatment Platform or a waitlist control condition
| Arm | Type | Receives |
|---|---|---|
| Ria Treatment Platfrom | Experimental | Combination Product: Ria Treatment PlatformThe Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer. |
| waitlist control | No intervention | –Patients in this arm will not be provided treatment during the study period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- alcohol use disorder
Key exclusion criteria (1 listed)
- inability to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ria Treatment Platformcombined medication, coaching, education, and monitoring | Combination product | Ria Treatment Platfrom |
Primary outcome
Percent of subjects without heavy drinking days
Time frame: Final 4 weeks of the 12-week trial period
Heavy drinking is defined as 5 or more standard drinks per day for men and 4 or more standard drinks per day for women, as assessed by the Timeline Followback.
2 secondary outcomes
Proportion of abstinent days
Time frame: 12-week trial period
Liver function (ALT, AST, GGT)
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
Related trials for Alcohol Use Disorder
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingPhase 1
Environment and Alcohol: A Pilot Study
Alcohol Use Disorder
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John Mendelson, MD principal investigator
Ria Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ria Treatment Platform in people with Alcohol Use Disorder and Alcohol Dependence, run by Ria Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent of subjects without heavy drinking days (time frame: Final 4 weeks of the 12-week trial period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.